INITIATIVES THAT IMPACT PRICING AND REIMBURSEMENT OF ORPHAN (AND ULTRA ORPHAN) DRUGS: REVIEW OF EUROPEAN TRENDS

被引：1
|
作者：
Rousseau, B. [1 ]
Poinas, A. [1 ]
Oliver, L. [1 ]
Collings, H. [1 ]
机构：
[1] Adelphi Values Ltd, Bollington, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1787
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP251
引用
收藏
页码：A695 / A696
页数：2
相关论文
共 50 条
  • [31] UNDERSTANDING THE PRICING AND REIMBURSEMENT (P&R) LANDSCAPE OF ORPHAN DRUGS IN EMERGING MARKETS
    Oliver, L.
    Karakusevic, A.
    Enstone, A.
    Rousseau, B.
    VALUE IN HEALTH, 2019, 22 : S860 - S861
  • [32] Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
    Malinowski, Krzysztof Piotr
    Kawalec, Pawel
    Trabka, Wojciech
    Czech, Marcin
    Petrova, Guenka
    Manova, Manoela
    Savova, Alexandra
    Draganic, Pero
    Vostalova, Lenka
    Slaby, Juraj
    Mannikg, Agnes
    Marky, Kristof
    Rugaja, Zinta
    Gulbinovic, Jolanta
    Tesar, Tomas
    Paveliu, Marian Sorin
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [33] ORPHAN DRUGS VERSUS ULTRA-ORPHAN DRUGS: PRICE COMPARISON IN ENGLAND
    Chachoua, L.
    Hanna, E.
    Zhou, J.
    Dussart, C.
    Toumi, M.
    VALUE IN HEALTH, 2018, 21 : S107 - S107
  • [34] Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
    Jakubowski, Szczepan
    Kawalec, Pawel
    Holko, Przemyslaw
    Kowalska-Bobko, Iwona
    Kamusheva, Maria
    Petrova, Guenka
    Draganic, Pero
    Fuksa, Leos
    Mannik, Agnes
    Ispan, Fanni
    Briedis, Vitalis
    Bianchi, Ioana
    Paveliu, Marian Sorin
    Tesar, Tomas
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [35] Orphan drugs: The European perspective
    Stathopoulos, Georgios
    ANNALS OF ONCOLOGY, 2006, 17 : 34 - 34
  • [36] Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
    Kolasa, Katarzyna
    Zwolinski, Krzysztof M.
    Kalo, Zoltan
    Hermanowski, Tomasz
    ORPHANET JOURNAL OF RARE DISEASES, 2016, 11
  • [37] Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
    Katarzyna Kolasa
    Krzysztof M. Zwolinski
    Zoltan Kalo
    Tomasz Hermanowski
    Orphanet Journal of Rare Diseases, 11
  • [38] The national drug formulary listing process for orphan drugs in South Korea: narrative review focused on pricing and reimbursement pathways
    Bang, Joon Seok
    Lee, Jong Hyuk
    EXPERT OPINION ON ORPHAN DRUGS, 2021, 9 (04): : 105 - 112
  • [39] TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5
    Prada, M.
    Berard, I
    Walzer, S.
    Darba, J.
    Greenwood, B.
    VALUE IN HEALTH, 2018, 21 : S264 - S264
  • [40] Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
    Rinke van den Brink
    Orphanet Journal of Rare Diseases, 9 (Suppl 1)
12345